BioCardia director receives 8,000 stock options

BioCardia, Inc. director Jim L. Allen received a grant of 8,000 stock options to buy common stock at an exercise price of $1.20 per share.

Rhea-AI Filing Summary

BioCardia, Inc. director Jim L. Allen received a grant of 8,000 stock options to buy common stock at an exercise price of $1.20 per share. These options vest and become exercisable in full on the one-year anniversary of the grant date, if he continues as a service provider through that date.

After this award, he holds 23,313 stock options in total. This is a compensation-related grant rather than an open-market stock purchase or sale.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Allen Jim L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 23,313 contracts (Direct)

Footnotes (1)

1. F1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

Key Figures

Options granted: 8,000 options Exercise price: $1.20 per share Total options after grant: 23,313 options +2 more

5 metrics

Options granted 8,000 options Stock Option (right to buy) grant on July 6, 2026

Exercise price $1.20 per share Exercise price for newly granted options

Total options after grant 23,313 options Total derivative holdings following transaction

Expiration date July 6, 2036 Option expiration for this grant

Transaction code A (Grant, award, or other acquisition) Indicates compensation-related acquisition, not open-market trade

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 1.2000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares are subject to the option vesting and becoming exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-07-06T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BioCardia (BCDA) director Jim L. Allen report?

Jim L. Allen reported receiving 8,000 stock options as a grant. The options give him the right to buy BioCardia common stock at a fixed exercise price as part of his director compensation package, rather than reflecting an open-market trade.

What is the exercise price of Jim L. Allen’s new BioCardia (BCDA) stock options?

The newly granted 8,000 stock options have an exercise price of $1.20 per share. This means Allen can purchase BioCardia common stock at $1.20 once the options vest, regardless of the market price at that future time.

When do Jim L. Allen’s newly granted BioCardia (BCDA) stock options vest?

All 8,000 stock options vest on the one-year anniversary of the grant date. Vesting is conditional on Allen continuing as a service provider to BioCardia through that date, after which the options become exercisable under their standard terms.

When do Jim L. Allen’s BioCardia (BCDA) stock options expire?

The newly granted options expire on July 6, 2036. After that date, any unexercised options become worthless, so Allen must exercise vested options before expiration if he chooses to purchase BioCardia common shares at the set price.

How many BioCardia (BCDA) stock options does Jim L. Allen hold after this grant?

Following the 8,000-option grant, Allen holds 23,313 stock options in total. This figure reflects his derivative position in BioCardia equity from options only, as reported in this Form 4, and does not describe any separate common share holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 09:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allen Jim L.

(Last) (First) (Middle)

C/O BIOCARDIA, INC.

320 SOQUEL WAY

(Street)

SUNNYVALE CALIFORNIA 94085

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BioCardia, Inc. [ BCDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.2	07/06/2026		A		8,000		(1)	07/06/2036	Common stock	8,000	$0	23,313	D

Explanation of Responses:

1. One hundred percent of the shares are subject to the option vesting and becoming exercisable on the one-year anniversary of the date of grant, subject to the Reporting Person continuing as a service provider through such date.

	/s/ David McClung, by power of attorney	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)